|
|
|
The diagnostics industry is undergoing a period of rapid transformation. Competitive pressures in the
basic core hospital laboratory are forcing large companies to reevaluate their franchises and seek
high-growth areas in which to compete. Smaller companies, armed with exciting innovations in POC
technologies and new assays, are confronting increased regulatory scrutiny, lengthy drug-like
development pathways, and a questionable reimbursement landscape. For all companies, capturing
value from the hype of personalized medicine in the form of novel biomarkers has been
difficult as scientific and commercial hurdles slow the progress of the field. Future
success in this industry will likely hinge on smart partnering approaches
between companies (diagnostic to diagnostic and drug to diagnostic), developing
compelling value-based pricing arguments with subsequent reimbursement from payers, and uniting stakeholders to realize the potential from all perspectives.
Health Advances works with diagnostic, therapeutic, and life science companies on novel commercialization strategies that address these dynamics.
From traditional clinical laboratory tests, to new biomarkers,
to cutting-edge imaging technology, to emerging translational technologies, Health Advances is at the
forefront in advising companies on how to extract the value their tests can create for the healthcare system.
- Corporate strategy
- Health economic analysis
- Market assessment
- Portfolio planning
- Pricing and reimbursement
- Product positioning
- Sales and marketing strategy
- Transaction due diligence
|
|
 |
|
|
|
|
